Switch theme
Sign up to access all valuation multiples
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China’s OTC pharmaceutical cross-border e-commerce market.
2023
n/a
Last FY Revenue $16.7M
Last FY EBITDA $2.5M
$14.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hong Kong Pharma achieved revenue of $16.7M and an EBITDA of $2.5M.
Hong Kong Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hong Kong Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $16.7M | XXX | XXX | XXX |
| Gross Profit | XXX | $3.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 21% | XXX | XXX | XXX |
| EBITDA | XXX | $2.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 15% | XXX | XXX | XXX |
| EBIT | XXX | $1.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | 10% | XXX | XXX | XXX |
| Net Profit | XXX | $1.3M | XXX | XXX | XXX |
| Net Margin | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | $0.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hong Kong Pharma's stock price is $1.
Hong Kong Pharma has current market cap of $12.9M, and EV of $14.9M.
See Hong Kong Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.9M | $12.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hong Kong Pharma has market cap of $12.9M and EV of $14.9M.
Hong Kong Pharma's trades at 0.9x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Hong Kong Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hong Kong Pharma's P/E ratio is not available.
See valuation multiples for Hong Kong Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.9M | XXX | $12.9M | XXX | XXX | XXX |
| EV (current) | $14.9M | XXX | $14.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 8.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 9.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -30.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHong Kong Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hong Kong Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hong Kong Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hong Kong Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| McMillan Shakespeare | XXX | XXX | XXX | XXX | XXX | XXX |
| Wipro | XXX | XXX | XXX | XXX | XXX | XXX |
| Alldigi Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| R Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Firstsource Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hong Kong Pharma acquired XXX companies to date.
Last acquisition by Hong Kong Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hong Kong Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hong Kong Pharma founded? | Hong Kong Pharma was founded in 2023. |
| Where is Hong Kong Pharma headquartered? | Hong Kong Pharma is headquartered in United States of America. |
| Who is the CEO of Hong Kong Pharma? | Hong Kong Pharma's CEO is Mr. Lap Sun Wong. |
| Is Hong Kong Pharma publicy listed? | Yes, Hong Kong Pharma is a public company listed on NAS. |
| What is the stock symbol of Hong Kong Pharma? | Hong Kong Pharma trades under HKPD ticker. |
| When did Hong Kong Pharma go public? | Hong Kong Pharma went public in 2025. |
| Who are competitors of Hong Kong Pharma? | Similar companies to Hong Kong Pharma include e.g. McMillan Shakespeare, Wipro, Alldigi Tech, R Systems. |
| What is the current market cap of Hong Kong Pharma? | Hong Kong Pharma's current market cap is $12.9M |
| Is Hong Kong Pharma profitable? | Yes, Hong Kong Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
